Pharmacy Benefit Manager Transparency Act of 2025

Bill Number

S. 526

Origin Chamber

Senate

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-02-11: Read twice and referred to the Committee on Commerce, Science, and Transportation.

Last Updated

2025-12-19T12:03:15Z

AI-Generated Summary

Purpose of the Legislation

The Pharmacy Benefit Manager Transparency Act of 2025 aims to increase transparency in pharmacy benefit management (PBM) services for prescription drugs. It seeks to prohibit unfair or deceptive pricing practices by PBMs (companies that manage prescription drug benefits for health plans), prevent the spread of false information to federal agencies, and promote fair competition in the pharmaceutical supply chain to potentially lower costs for consumers and payers.

Key Provisions

• Prohibitions on Unfair Pricing Practices (Section 2): Makes it unlawful for PBMs (or their affiliates, subsidiaries, or agents) to:
• Charge health plans or payers more for a drug's ingredient cost or dispensing fee (the fee for filling a prescription) than what they reimburse pharmacies, if the PBM keeps the difference (known as "spread pricing").
• Arbitrarily reduce, rescind, or "claw back" (take back) reimbursements to pharmacies unless due to fraud, contract inconsistencies, or unrendered services.
• Increase fees or lower reimbursements to pharmacies to offset federal government-mandated changes in federally funded health plans.
• Exceptions: Allowed if PBMs pass 100% of price concessions (like rebates or discounts) to health plans and fully disclose costs, fees, and manufacturer payments.

• Prohibition on False Information (Section 3): Bans reporting false or misleading data about PBM services to federal agencies if the reporter knew or should have known it was inaccurate, the data was legally required, and it could skew federal market analysis.

• Transparency Requirements (Section 4):
• PBMs must annually report to the Federal Trade Commission (FTC) and Secretary of Health and Human Services details like payment differences between health plans and pharmacies, fees charged to pharmacies, clawbacks, reasons for moving drugs to higher-cost formulary tiers (lists of covered drugs with cost levels), and differences in treatment for affiliated vs. independent pharmacies.
• FTC must report annually to Congress on enforcement actions, investigations, complaints, anonymized PBM reports, merger impacts on competition, and recommendations to strengthen the law or boost competition.
• FTC must submit a separate report on PBM formulary design practices, including whether they prioritize high-rebate drugs over cheaper options without benefiting patients.
• Government Accountability Office (GAO) must conduct a study on PBM roles, competition, rebate usage, formulary structuring, prior authorizations (approvals needed before filling certain prescriptions), step therapy (requiring cheaper drugs first), pricing spreads, and competitive impacts, with recommendations to lower drug costs and improve efficiency.
• Reports must protect privacy under HIPAA (Health Insurance Portability and Accountability Act) rules.

• Whistleblower Protections (Section 5): Prohibits PBMs, health plans, drug manufacturers, or pharmacies from retaliating against employees, contractors, or agents who report suspected violations to authorities, supervisors, or investigators. Violations allow whistleblowers to sue for reinstatement, back pay (doubled), damages, and legal fees. These rights cannot be waived, and predispute arbitration agreements (pre-agreed private dispute resolution) are unenforceable for these claims.

• Enforcement (Section 6):
• FTC enforces violations as unfair or deceptive acts under the Federal Trade Commission Act, with expanded jurisdiction over nonprofits and the insurance business (overriding some prior limits). Penalties include up to $1,000,000 per violation, with daily ongoing violations counted separately; courts consider severity, remediation efforts, and intent.
• State attorneys general (or other authorized officials) can sue on behalf of residents, with notice to FTC and potential FTC intervention. Actions must not conflict with ERISA (Employee Retirement Income Security Act, governing employee benefits).
• Affirmative defense available if practices were necessary to comply with law, protect patient safety, or ensure access.

• Protections and Other Rules (Sections 7-9):
• Disclosures cannot include patient or prescriber identifying information.
• Does not preempt state laws.
• Defines key terms like "PBM" (entity managing drug benefits for health plans), "health plan" (insurance covering drugs, including government programs), and "prescription drug" (FDA-approved medications requiring a prescription).

Significant Changes to Existing Law

• Introduces specific federal prohibitions on PBM spread pricing, clawbacks, and fee manipulations, which were not explicitly banned before, though some states have similar rules.
• Mandates new annual reporting by PBMs and detailed federal studies/reports, filling gaps in transparency under existing laws like the Federal Trade Commission Act.
• Expands FTC authority to cover nonprofits and insurance, bypassing parts of the McCarran-Ferguson Act (which limits federal oversight of insurance).
• Adds whistleblower protections tailored to PBM violations, including bans on waiving rights via arbitration, strengthening employee safeguards beyond general labor laws.
• Imposes civil penalties up to $1 million, higher than standard FTC fines for similar acts.

Potential Impacts

• Government Agencies: Increases workload for FTC (enforcement, reporting) and HHS (receiving reports); GAO and Congressional Budget Office gain access to data for reviews. Could lead to more informed policymaking on drug pricing in programs like Medicare and Medicaid.
• Citizens: May lower prescription drug costs and out-of-pocket expenses by curbing PBM profits from spreads and rebates, improving access through fairer reimbursements to pharmacies and reduced formulary manipulations. Enhances consumer protections via whistleblower incentives and state enforcement.
• International Relations: No direct impacts mentioned; focuses on domestic pharmaceutical supply chain.

Main Stakeholders Affected

• Pharmacy Benefit Managers (PBMs): Face new restrictions, reporting burdens, and penalties; must adjust pricing and disclosure practices.
• Pharmacies and Pharmacists: Benefit from protections against unfair reimbursements and clawbacks, potentially stabilizing operations, especially for independent pharmacies vs. PBM-affiliated ones.
• Health Plans and Payers (e.g., insurers, employers, government programs like Medicare/Medicaid): Gain from full rebate pass-throughs and transparency, possibly reducing premiums.
• Pharmaceutical Manufacturers: Affected by disclosures of rebates and formulary influences; may face scrutiny on drug placement requests.
• Consumers/Patients: Indirectly benefit from potential cost savings and better drug access.
• Federal and State Governments: FTC, HHS, and states gain enforcement tools; Congress receives data for oversight.
• Whistleblowers/Employees: Protected from retaliation in reporting violations.

Notable Legal, Constitutional, or Political Implications

• Legal: Treats violations as unfair trade practices, enabling FTC rulemaking and lawsuits; state actions preserve federalism without ERISA conflicts. Affirmative defenses balance compliance needs. Confidentiality protections align with trade secret laws (e.g., Freedom of Information Act exemptions) and HIPAA.
• Constitutional: No direct challenges noted; enhances due process via jury trials for whistleblowers and judicial review of penalties. Expands federal oversight of insurance without fully displacing states, respecting 10th Amendment federalism.
• Political: Bipartisan sponsorship (e.g., Grassley, Cantwell) signals broad support for drug pricing reform. Encourages competition to prevent PBM monopolies (top 10 PBMs dominate market), potentially influencing antitrust enforcement. Recommendations in reports could spur future legislation on formularies, rebates, and supply chain efficiency.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Grassley, Chuck [R-IA]

Cosponsors (14)

Sen. Cantwell, Maria [D-WA], Sen. Ernst, Joni [R-IA], Sen. Welch, Peter [D-VT], Sen. Capito, Shelley Moore [R-WV], Sen. Shaheen, Jeanne [D-NH], Sen. Marshall, Roger [R-KS], Sen. Heinrich, Martin [D-NM], Sen. Moran, Jerry [R-KS], Sen. Hyde-Smith, Cindy [R-MS], Sen. Tillis, Thomas [R-NC], Sen. Rounds, Mike [R-SD], Sen. Boozman, John [R-AR], Sen. Gallego, Ruben [D-AZ], Sen. Warnock, Raphael G. [D-GA]

Recent Actions

• 2025-02-11: Read twice and referred to the Committee on Commerce, Science, and Transportation.
• 2025-02-11: Introduced in Senate

Bill Versions

• Pharmacy Benefit Manager Transparency Act of 2025 — issued 2025-02-11 — PDF (25 pages)